We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Here are some of the stocks on the move on Monday, June 2. Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) ...

The French pharmaceutical giant is acquiring a Cambridge biotech and its rare immunology disease which is already approved in ...

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an ...

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Sanofi SA SNY announced plans to acquire Blueprint Medicines for $9.5 billion. Blueprint Medicines shares jumped 26.9% to ...

The stock, trading under the ticker (NASDAQ:BPMC), is a part of both the Nasdaq Biotechnology Index and the Nasdaq Today.